NSETrading Window29 Sept 2026 · 29 Sept 2026, 05:15 pm
Trading Window
Jubilant Pharmova Limited · JUBLPHARMA
✦ AI Summary
Jubilant Pharmova Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
Analysis Scores
Earnings Impact5/10
Growth Catalyst5/10
Governance Concern5/10
Regulatory Risk5/10
Balance Sheet Risk5/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Jubilant Pharmova Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Attachments (1)
📄pdf
Download →
JUBLPHARMA_29092026171506_ClosureofTradingWindowsigned.pdf
View document text
September 29, 2026
BSE Limited National Stock Exchange of India Limited
Floor 25, P. J. Towers Exchange Plaza
Dalal Street, Fort Bandra Kurla Complex
Mumbai - 400 001 Bandra (E)
Mumbai - 400 051
Scrip Code: 530019 Trading Symbol: JUBLPHARMA
Sub: Intimation regarding closure of Trading Window
Dear Sir/Madam,
Pursuant to Regulation 9 read with Schedule B of the SEBI (Prohibition of Insider Trading) Regulations, 2015
and the Company's Code of Conduct for Prevention of Insider Trading for regulating, monitoring and reporting
of trading by insiders, the Trading Window for dealing in the securities of Jubilant Pharmova Limited
("Company") shall remain closed for all Designated Persons and their Immediate Relatives with effect from
Thursday, October 1, 2026 and shall continue to remain closed till 48 hours after the declaration of the
unaudited standalone and consolidated financial results of the Company for the quarter and half year ended
September 30, 2026 to the Stock Exchanges.
Accordingly, the Designated Persons have been intimated not to trade in the securities of the Company during
the aforesaid period of Trading Window closure.
The date of the Board Meeting for consideration and approval of the unaudited standalone and consolidated
financial results of the Company for the quarter and half year ended September 30, 2026 shall be intimated to
the Stock Exchanges in due course.
The above information shall also be made available on the website of the Company at
www.jubilantpharmova.com.
This is for your information and records.
Thanking you,
Yours faithfully,
For Jubilant Pharmova Limited
Naresh Kapoor
Company Secretary